NeoGenomics, Inc. (NEO) fair value analysis
Nasdaq · Updated 2026-09-07
NeoGenomics, Inc. is a clinical laboratory company that provides genomic testing services, including cancer diagnostics and other molecular testing for oncology and inherited conditions. The company operates testing facilities in the United States and serves healthcare providers and patients across the country.
Valuation status
Awaiting full valuationNEO does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $15.84
- Sector
- Healthcare
- 12-month range
- $7.75–$15.84
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- C
- Leverage
- Low
- Margin trend
- Stable
- Revenue growth
- Strong
- RSI zone
- Neutral
- 50/200-day trend
- Uptrend
- 52-week position
- The top quarter of its range
What our data shows for NEO
- Our model validated 1 trailing price-to-earnings windows for NEO, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $7.75–$15.84.
- The 14-day relative strength index sits at a neutral 58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for NEO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent NEO news
TickrTrends' derived news-sentiment signal for NEO is currently leaning positive, computed from recent coverage.
- NeoGenomics Inc (NEO) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 73/100 (gurufocus.com, 2026-08-26)
TickrTrends take: NeoGenomics trades in the Healthcare sector where valuation metrics carry particular weight given the industry's sensitivity to clinical validation and reimbursement changes. With TickrTrends currently awaiting full valuation for NEO, the recent stock movement paired with GF Value's overvaluation assessment suggests that investors focused on valuation should monitor whether the company's fundamentals can support its current price level. A valuation-focused reader should track whether upcoming earnings or clinical developments provide justification for the stock's positioning or whether valuation pressure may intensify. - NEO Looks 8.2% Overvalued on GF Value™ (gurufocus.com, 2026-08-26)
TickrTrends take: NEO's valuation assessment indicates the stock may be trading above its estimated fair value by approximately 8 percent based on GF Value analysis. Given that TickrTrends is currently awaiting full valuation data on this healthcare company, investors focused on valuation metrics should monitor whether additional analysis will confirm or diverge from this overvaluation signal. The gap between current price and estimated value represents a metric that valuation-conscious investors typically track when evaluating entry and exit points in the healthcare sector. - NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run? (zacks.com, 2026-08-24)
TickrTrends take: NeoGenomics operates in the Healthcare sector and has recently reached a fresh high, which typically warrants examination of whether current valuations reflect the company's fundamental performance or represent momentum-driven pricing. With TickrTrends currently awaiting full valuation on NEO, investors focused on valuation metrics should monitor whether the company's earnings growth and revenue expansion can justify price levels at these new highs. Understanding the relationship between NEO's recent price strength and its underlying business fundamentals will be essential once a complete valuation assessment becomes available.
What people are saying
Follow the NEO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is NEO stock undervalued?
NEO does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is NEO's TickrTrends verdict?
NEO is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is NEO overbought or oversold?
NEO's 14-day RSI is in neutral territory - neither overbought nor oversold.